ALVO:NSD-Alvotech Ordinary Shares (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 9.25

Change

+0.11 (+1.20)%

Market Cap

USD 2.27B

Volume

0.13M

Avg Analyst Target

USD 14.33 (+54.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALVO Stock Forecast & Price:
Based on the Alvotech Ordinary Shares stock forecasts from 3 analysts, the average analyst target price for Alvotech Ordinary Shares is USD 14.33 over the next 12 months. Alvotech Ordinary Shares’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alvotech Ordinary Shares is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Alvotech Ordinary Shares’s stock price was USD 9.25. Alvotech Ordinary Shares’s stock price has changed by +23.33% over the past week, +67.27% over the past month and 0% over the last year.

About Alvotech Ordinary Shares (ALVO:NSD)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration f ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX Neurocrine Biosciences Inc

-1.28 (-1.19%)

USD10.27B 826.08 212.29
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
LNTH Lantheus Holdings Inc

-0.32 (-0.38%)

USD5.75B 199.29 50.44
ITCI Intracellular Th

+1.28 (+2.44%)

USD4.96B N/A -15.27
PCRX Pacira Pharmaceuticals Inc

+0.22 (+0.38%)

USD2.65B 68.73 22.46
HCM HUTCHMED DRC

-0.24 (-1.73%)

USD2.40B 17.69 -5.96
TLRY Tilray Inc

-0.09 (-2.10%)

USD2.34B 9.83 -10.33
DVAX Dynavax Technologies Corporati..

-1.38 (-8.83%)

USD1.98B 9.89 7.28

ETFs Containing ALVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.27B 92% A- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -9.96 83% B 76% C
EV/EBITDA -134.36 97% A+ 97% A+
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 1,103.02% 100% A+ 99% A+
Return on Assets -26.74% 33% F 16% F
Debt to Equity Ratio -293.59% 92% A- 96% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.45 72% C- 73% C
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.